相关实验视频
Updated: Jan 11, 2026

06:13
The Intra-Aortic Balloon Pump
Published on: February 5, 2021
24.2K
在急性心肌梗塞中使用伊瓦布拉丁控制心率:一种倾向性得分匹配的单中心研究
Meixian Chen1, Peiqi Zhong1, Chao Li1
1Department of Cardiology, 900th Hospital of PLA Joint Logistic Support Force, Fuzong Clinical Medical College of Fujian Medical University, Fuzhou, 350025, Fujian, China.
Scientific reports
|November 12, 2025
概括
艾瓦布拉丁在急性心肌梗塞 (AMI) 患者的治疗与减少住院治疗有关. 这些真实世界的数据表明潜在的好处,特别是在特定的子组,保证进一步调查心率控制策略.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 现实世界的证据.
背景情况:
- 在急性心肌梗塞 (AMI) 患者中,伊瓦布拉丁对心率控制的临床实用性正在进行辩论.
- 在评估不同患者群体中药理干预措施的有效性和安全性方面,现实数据至关重要.
研究的目的:
- 评估艾瓦布拉丁治疗与急性心肌梗塞后患者重新住院的风险之间的关联.
- 为了确定患者子组,谁可能会从艾瓦布拉丁治疗最受益心率管理后AMI.
主要方法:
- 对408名AMI患者的真实世界数据的回顾性分析,其中76人接受了伊瓦布拉丁.
- 统计分析包括卡普兰-梅尔,日志等级测试,多变量考克斯回归和倾向得分匹配 (PSM).
- 进行了子组分析和相互作用测试,以探索艾瓦布拉丁对各种风险因素的影响.
主要成果:
- 在PSM之前,伊瓦布拉丁与所有原因再入院的风险降低有关 (HR:0.64).
- 在PSM之后,这种关联在统计上没有显著性 (HR:0.79).
- 在特定的亚组中观察到重住院风险的显著降低:女性,心率> 70 bpm的患者,基利普类> 1,前壁MI,> 1 个患病的血管,没有CKD,并且不服用克洛皮多格雷尔.
- 在出院时达到目标心率与更低的再入院相关 (HR:0.74).
- 多变量分析表明,艾瓦布拉丁在12个月内降低了重新住院的风险 (aHR:0.80).
结论:
- 在AMI住院期间的伊瓦布拉丁治疗似乎与所有原因再住院的风险较低有关.
- 观察到的益处在特定的患者亚组中更为明显,这表明个性化治疗方法.
- 需要进一步验证以确认这些发现的稳定性和临床影响.
相关概念视频
Dysrhythmias VI: Management of Dysrhythmias
422
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
422
Cardiopulmonary Resuscitation IV: Pharmacological Management
623
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
623
Decreased pulse rate
828
Bradycardia is a medical condition in which the heart rate is slower than normal. It occurs when the heart's natural pacemaker, the sinus node, generates slower electrical impulses than the standard rhythm. In adults, bradycardia is diagnosed when the pulse rate falls below 60 beats per minute, indicating a deviation from the normal heart rate range.
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
828
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
1.5K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.5K
Heart Failure V: Medical Management
207
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
207
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.4K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.4K

